Biotech | August 30, 2021
Vivo Bio Tech enters long-term contract with Bio E
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The segment delivered strong sales growth of 20% YoY
The facility has the capacity to produce one crore doses per day
This is Enzene Biosciences third biosimilar to be approved
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
This facility will integrate with existing Max hospitals and create a 2,300-bed contiguous medical hub spread over 23 acres. The first phase is to be ready by 2024
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually
Subscribe To Our Newsletter & Stay Updated
